Dernières publications scientifiques

  • Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.

  • Auteurs Ogbogu PU, Roufosse F, Akuthota P, Kuna P, Groh M, Reiter A, Yokota A, Siddiqui SH, Mutsaers PGNJ, Li B, Khoury P, Bahadori LM, Bednarczyk A, Bouma G, Brooks LG, Ferreira J, Grindebacke H, Ho CN, Jain P, Palmer RL, Jison ML, Klion AD
  • Revue Nat Med
  • Date de publication 2026-05
Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.
  • ChatGPT, Gemini, and Claude in clinical and dermoscopic image analysis of basal cell carcinoma and its common mimickers: A comparative performance analysis.

  • Auteurs Boostani M, Zouboulis CC, Pellacani G, Navarrete-Dechent C, Boussingault L, Kiss T, Goldfarb N, Cantisani C, Nádudvari N, Bánvölgyi A, Wikonkál NM, Suppa M, Paragh G, Kiss N
  • Revue JID Innov
  • Date de publication 2026-05
ChatGPT, Gemini, and Claude in clinical and dermoscopic image analysis of basal cell carcinoma and its common mimickers: A comparative performance analysis.
Bordet hospital

Institut Jules Bordet

Consultez toutes les publications scientifiques de Jules Bordet

Erasme hospital

Hôpital Erasme

Consultez toutes les publications scientifiques d'Erasme

Huderf hospital

Hôpital pédiatrique Reine Fabiola

Voir toutes les publications scientifiques de l'Hôpital pédiatrique Reine Fabiola